Rigel Pharmaceuticals (RIGL) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Rigel Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$116.88M

Latest Revenue (Q)

$55.31M

Main Segment (Y)

Gross product sales

Rigel Pharmaceuticals Revenue by Period

Rigel Pharmaceuticals Revenue by Year

Date	Revenue	Change
2023-12-31	$116.88M	-2.79%
2022-12-31	$120.24M	-19.43%
2021-12-31	$149.24M	37.39%
2020-12-31	$108.62M	83.21%
2019-12-31	$59.29M	33.20%
2018-12-31	$44.51M	892.62%
2017-12-31	$4.48M	-78.00%
2016-12-31	$20.38M	-29.46%
2015-12-31	$28.89M	250.24%
2014-12-31	$8.25M	15.38%
2013-12-31	$7.15M	217.78%
2012-12-31	$2.25M	-52.63%
2011-12-31	$4.75M	-96.20%
2010-12-31	$125.00M	16566.67%
2009-12-31	$750.00K	100.00%
2008-12-31	-	-100.00%
2007-12-31	$12.60M	-62.36%
2006-12-31	$33.47M	102.55%
2005-12-31	$16.53M	249.17%
2004-12-31	$4.73M	-57.19%
2003-12-31	$11.05M	-29.98%
2002-12-31	$15.79M	3.17%
2001-12-31	$15.30M	15.77%
2000-12-31	$13.22M	47.13%
1999-12-31	$8.98M	-

Rigel Pharmaceuticals generated $116.88M in revenue during NA 2023, up -2.79% compared to the previous quarter, and up 262.60% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$55.31M	50.12%
2024-06-30	$36.84M	24.74%
2024-03-31	$29.53M	-17.48%
2023-12-31	$35.79M	27.22%
2023-09-30	$28.13M	4.64%
2023-06-30	$26.89M	3.13%
2023-03-31	$26.07M	-49.16%
2022-12-31	$51.28M	128.82%
2022-09-30	$22.41M	-24.85%
2022-06-30	$29.82M	78.18%
2022-03-31	$16.73M	-18.00%
2021-12-31	$20.41M	-5.26%
2021-09-30	$21.54M	-17.98%
2021-06-30	$26.27M	-67.58%
2021-03-31	$81.02M	339.12%
2020-12-31	$18.45M	0.33%
2020-09-30	$18.39M	14.78%
2020-06-30	$16.02M	-71.27%
2020-03-31	$55.76M	262.08%
2019-12-31	$15.40M	-26.16%
2019-09-30	$20.86M	100.41%
2019-06-30	$10.41M	-17.56%
2019-03-31	$12.62M	-66.65%
2018-12-31	$37.86M	678.15%
2018-09-30	$4.87M	172.24%
2018-06-30	$1.79M	100.00%
2018-03-31	-	100.00%
2017-12-31	-	-100.00%
2017-09-30	$900.00K	100.00%
2017-06-30	-	-100.00%
2017-03-31	$3.58M	19.47%
2016-12-31	$3.00M	-20.21%
2016-09-30	$3.76M	-56.25%
2016-06-30	$8.59M	70.89%
2016-03-31	$5.03M	-41.09%
2015-12-31	$8.54M	-34.31%
2015-09-30	$13.00M	150.69%
2015-06-30	$5.18M	138.02%
2015-03-31	$2.18M	-73.60%
2014-12-31	$8.25M	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	-100.00%
2013-12-31	$5.75M	100.00%
2013-09-30	-	-100.00%
2013-06-30	$1.40M	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	-100.00%
2012-06-30	$1.50M	100.00%
2012-03-31	$750.00K	100.00%
2011-12-31	-	-100.00%
2011-09-30	$4.36M	1002.53%
2011-06-30	$395.00K	100.00%
2011-03-31	-	100.00%
2010-12-31	-	-100.00%
2010-09-30	$72.28M	46.15%
2010-06-30	$49.46M	1416.62%
2010-03-31	$3.26M	334.80%
2009-12-31	$750.00K	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	-100.00%
2007-12-31	$8.00M	-

Rigel Pharmaceuticals generated $55.31M in revenue during Q3 2024, up 50.12% compared to the previous quarter, and up 205.71% compared to the same period a year ago.

Rigel Pharmaceuticals Revenue Breakdown

Rigel Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Discounts and allowances	$-42.76M	$-31.80M	$-18.18M	-	-
Government contracts	$1.10M	-	-	-	-
Gross product sales	$147.06M	$108.52M	$81.19M	-	-
Milestone	$75.00K	-	-	-	-
Product sales, net	$104.29M	$76.72M	$63.01M	-	-
Revenues from collaborations	$11.49M	-	-	-	-
License revenues	-	$7.93M	$70.55M	-	-
Research and development services and others	-	$6.09M	$3.30M	-	-
Development milestones	-	$25.00M	$1.88M	-	-
Contract revenues from collaborations	-	$39.02M	$75.73M	-	-
Government contract	-	$4.50M	$10.50M	-	-
License	-	-	-	$40.36M	$8.70M
Contract Revenues From Collaborations	-	-	-	$46.92M	$15.52M
Development Milestones	-	-	-	$2.10M	$5.50M
Discounts And Allowances	-	-	-	$-14.77M	$-9.31M
Gross Product	-	-	-	$76.47M	$53.08M
Research And Development Services And Others	-	-	-	$4.47M	$1.32M
Product	-	-	-	$61.70M	$43.77M

Rigel Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Gross product sales (66.47%), Product sales, net (47.14%), Revenues from collaborations (5.19%), Government contracts (0.50%), Milestone (0.03%), and Discounts and allowances (-19.33%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Discounts and allowances	$-17.39M	$-12.42M	-	$-9.57M	$-9.45M	$-9.72M	$-7.79M	$-7.88M	$-6.42M	$-4.92M	-	-	-	-	-	-	-	-	-	-
Revenues from collaborations	$16.38M	$3.53M	$722.00K	$11.27M	$538.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product sales, net	$38.93M	$26.00M	$56.67M	$23.88M	$23.75M	$22.78M	$19.19M	$18.55M	$16.20M	$17.57M	-	-	-	-	-	-	-	-	-	-
License	$10.00M	$2.43M	$3.31M	$64.62M	$-1.60M	$2.10M	-	$39.86M	$-3.55M	$7.75M	$4.50M	-	-	-	-	-	-	-	-	-
Gross product sales	$56.32M	$38.43M	$80.40M	$33.46M	$33.20M	$32.50M	$26.98M	$26.43M	$22.62M	$22.49M	-	-	-	-	-	-	-	-	-	-
Contract revenues from collaborations	-	-	-	$2.00M	$2.33M	$26.50M	$1.84M	-	-	-	-	-	-	-	-	-	-	-	-	-
Government contract	-	-	-	$1.00M	$2.00M	$2.50M	$1.00M	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development services and others	-	-	-	-	-	$1.11M	$722.00K	$3.93M	$330.00K	$1.64M	-	-	-	-	-	-	-	-	-	-
Development milestones	-	-	-	-	-	$20.00M	-	$5.00M	-	-	-	-	-	-	-	-	-	-	-	-
License revenues	-	-	-	-	-	$5.39M	-	$2.34M	$208.00K	$199.00K	-	-	-	-	-	-	-	-	-	-
Contract Revenues From Collaborations	-	-	-	-	-	-	-	-	-	-	$4.53M	$3.71M	$65.64M	$697.00K	$2.10M	$1.05M	$43.08M	$1.57M	$9.14M	$234.00K
Research And Development Services And Others	-	-	-	-	-	-	-	-	-	-	$225.00K	$408.00K	$1.02M	$197.00K	-	$1.05M	$3.22M	$-376.00K	$1.39M	-
Product	-	-	-	-	-	-	-	-	-	-	$16.01M	$17.05M	$12.38M	$17.75M	$16.29M	$14.97M	$12.68M	$13.83M	$11.72M	$10.17M
Gross Product	-	-	-	-	-	-	-	-	-	-	$20.55M	$22.04M	$16.11M	$22.43M	$20.32M	$18.35M	$15.37M	$16.34M	$14.35M	$12.48M
Government Contract	-	-	-	-	-	-	-	-	-	-	$1.00M	$5.50M	$3.00M	-	-	-	-	-	-	-
Discounts And Allowances	-	-	-	-	-	-	-	-	-	-	$-4.53M	$-4.98M	$-3.73M	$-4.67M	$-4.03M	$-3.38M	$-2.69M	$-2.51M	$-2.63M	$-2.31M
Development Milestones	-	-	-	-	-	-	-	-	-	-	$1.88M	-	-	-	-	-	-	-	-	-
Research And Development Services	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$234.00K

Rigel Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Gross product sales (54.03%), Product sales, net (37.35%), Revenues from collaborations (15.71%), License (9.59%), and Discounts and allowances (-16.69%).

Rigel Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RIGL	Rigel Pharmaceuticals	$116.88M	$55.31M
CDTX	Cidara Therapeutics	$63.91M	-
FBIO	Fortress Biotech	$59.66M	$14.63M
PIRS	Pieris Pharmaceuticals	$42.81M	-
MREO	Mereo BioPharma Group	$10.00M	-
XFOR	X4 Pharmaceuticals	-	$560.00K
RVPH	Reviva Pharmaceuticals	-	-
DAWN	Day One Biopharmaceuticals	-	$20.07M
ZURA	Zura Bio	-	-
ABOS	Acumen Pharmaceuticals	-	-
INZY	Inozyme Pharma	-	-
LPTX	Leap Therapeutics	-	-
ELEV	Elevation Oncology	-	-
TERN	Terns Pharmaceuticals	-	-
IMMX	Immix Biopharma	-	-
ENVB	Enveric Biosciences	-	-

RIGL Revenue FAQ

What is Rigel Pharmaceuticals’s yearly revenue?

Rigel Pharmaceuticals's yearly revenue for 2023 was $116.88M, representing a decrease of -2.79% compared to 2022. The company's yearly revenue for 2022 was $120.24M, representing a decrease of -19.43% compared to 2021. RIGL's yearly revenue for 2021 was $149.24M, representing an increase of 37.39% compared to 2020.

What is Rigel Pharmaceuticals’s quarterly revenue?

Rigel Pharmaceuticals's quarterly revenue for Q3 2024 was $55.31M, a 50.12% increase from the previous quarter (Q2 2024), and a 96.58% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $36.84M, a 24.74% increase from the previous quarter (Q1 2024), and a 37.03% increase year-over-year (Q2 2023). RIGL's quarterly revenue for Q1 2024 was $29.53M, a -17.48% decrease from the previous quarter (Q4 2023), and a 13.29% increase year-over-year (Q1 2023).

What is Rigel Pharmaceuticals’s revenue growth rate?

Rigel Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -21.68%, and for the last 5 years (2019-2023) was 97.14%.

What are Rigel Pharmaceuticals’s revenue streams?

Rigel Pharmaceuticals's revenue streams in c 23 are Discounts and allowances, Government contracts, Gross product sales, Milestone, Product sales, net, and Revenues from collaborations. Discounts and allowances generated $-42.764M in revenue, accounting -19.33% of the company's total revenue, up 34.46% year-over-year. Government contracts generated $1.1M in revenue, accounting 0.50% of the company's total revenue Gross product sales generated $147.06M in revenue, accounting 66.47% of the company's total revenue, up 35.51% year-over-year. Milestone generated $75K in revenue, accounting 0.03% of the company's total revenue Product sales, net generated $104.29M in revenue, accounting 47.14% of the company's total revenue, up 35.94% year-over-year. Revenues from collaborations generated $11.49M in revenue, accounting 5.19% of the company's total revenue

What is Rigel Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Rigel Pharmaceuticals was Gross product sales. This segment made a revenue of $147.06M, representing 66.47% of the company's total revenue.